ArticleScientific reports2025
Biopharmaceutical characterization of Ajwain (Carum copticum) seed extract-loaded self-microemulsifying drug delivery system for enhanced hepatoprotective and nephroprotective activity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The increasing demand for plant-based therapies has highlighted the need for innovative delivery technologies to enhance the bioavailability of phytoconstituents. Ajwain (Carum copticum) is a medicinal plant recognized for its antioxidant, anti-inflammatory, and hepatoprotective attributes. Nevertheless, its therapeutic application is greatly affected by insufficient aqueous solubility and low absorption. Targeting the biopharmaceutical performance improvement of Ajwain seed extract (ASE) by integrating it into a self-microemulsifying drug delivery system (SMEDDS) was considered, along with assessing its protective effects. ASE underwent GC-MS analysis for phytochemical profiling, followed by solubility assessment in several oils, surfactants, and co-surfactants. The improved SMEDDS-ASE was characterized physicochemically for micelle formation potential, dispersibility, gastrointestinal stability, and polymer miscibility with ASE. The hepatorenal protective effects were evaluated in a rat model of acute hepatorenal injury generated by cisplatin (7.5 mg/kg, i.p.) through the assessment of serum biomarkers and histological analysis. SMEDDS-ASE exhibited the formation of tiny micelles with an average droplet size of 183 ± 5.8 nm in water, resulting in a dispersibility enhancement of at least 2.4 times compared to ASE in water. The treatment of SMEDDS-ASE (75 mg/kg and 150 mg/kg, p.o.) significantly reduces different serum biomarker levels (decreased ALT, AST, ALP; p < 0.01; reduced creatinine, BUN; p < 0.05), which is ascribed to improved hepatorenal protection in a dose-dependent manner compared to ASE. Histological examinations suggest that SMEDDS-ASE may initiate the protection of hepatic and renal cells against damage and inflammation, thereby offering benefits in preventing diseases associated with free radicals. These findings suggest that the prospective implementation of the SMEDDS-based method may effectively enhance ASE's nutraceutical properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.